Pse-T2-Based Short Peptides with Broad-Spectrum Antimicrobial Activity, Stability, and Safety Combat MDR...

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Rising global infections caused by multi-drug resistant (MDR) pathogens pose a significant threat.
• Conventional antibiotics are becoming less effective, necessitating novel therapeutic strategies.
• There is an urgent need for new agents to combat MDR bacterial infections.

Purpose of the Study:

• To evaluate the efficacy of a functional truncated peptide, Pse-T2-C12, against MDR pathogens.
• To investigate the mechanism of action, stability, toxicity, and resistance potential of Pse-T2-C12.
• To assess the therapeutic potential of Pse-T2-C12 in a preclinical model of MDR bacterial infection.

Main Methods:

• Functional truncated peptide Pse-T2-C12 was synthesized and tested.
• Antibacterial, antibiofilm, and antipersister activities were assessed.
• Mechanism of action, stability (pH, temperature, serum), toxicity (in vitro and in vivo), and resistance development were evaluated.
• In vivo efficacy was tested in a mouse model of Staphylococcus aureus infection.

Main Results:

• Pse-T2-C12 demonstrated potent antibacterial, antibiofilm, and antipersister activities with rapid killing rates.
• The peptide acts by forming pores, permeabilizing, and disrupting bacterial membranes.
• Pse-T2-C12 showed stability under various conditions and no detectable toxicity.
• No resistance development was observed.
• In vivo, Pse-T2-C12 significantly reduced Staphylococcus aureus infection, inflammation, coagulation, and pain.

Conclusions:

• Pse-T2-C12 is a highly effective antimicrobial agent with a novel mechanism of action.
• The peptide exhibits favorable stability, safety, and lack of resistance development.
• Pse-T2-C12 represents a promising therapeutic candidate for treating MDR bacterial infections.
• Easy synthesis and economic benefits further support its potential clinical application.